Home > Insider Trading > Filing (0000947871-21-000986)

Filing Details

Accession Number:: 0000947871-21-000986
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-08 18:18:30
Reporting Period:: 2021-09-03

Accepted Time:: 2021-09-08 18:18:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022-4629	Yes	No	No	No
1157524	Orbimed Capital Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	No	No
1760648	Orbimed Capital Gp Vii Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-03	6,985	$34.00	3,177,902	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-09-03	212	$34.00	96,216	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-09-07	861	$33.93	3,177,041	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-09-07	26	$33.93	96,190	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VII, LP ("OPI VII").
These shares of the Issuer's common stock are held of record by OPI VII. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. OrbiMed Advisors and GP VII exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
These shares of the Issuer's common stock were sold in a block order at price of $34.00 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Partners Master Fund Limited ("OPM").
These shares of the Issuer's common stock are held of record by OPM. OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
This report on Form 4 is jointly filed by GP VII, OrbiMed Advisors, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPI VII.
These shares of the Issuer's common stock were sold in a block order at price of $33.93 pursuant to a Rule 10b5-1 trading plan established by OPM.